SciClone Pharmaceuticals (Holdings) Ltd. is an investment holding company which manufactures and markets immune and oncology pharmaceutical products. The company is headquartered in Shanghai, Shanghai and currently employs 1,050 full-time employees. The firm and its subsidiaries are principally engaged in developing and commercializing a portfolio of marketed products as well as pipelines with potential in their focused therapeutic areas including oncology and severe infection. The Company’s main products comprise Zadaxin, Zometa, Oravig, Angiomax, Endoxan, Holoxan, Cytosafe, Farlutal, Campto and Vizimpro. The Company’s pipeline products include ORSERDU, Vaborem, Vibativ, RRx-001 and Omburtamab. The Company’s products are mainly used in fields such as tumors, urinary tract infections, and skin and soft tissue infections. The firm mainly conducts its businesses in the domestic market.